These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 7259691)

  • 41. Efficacy of histaminergic drugs in experimental motion sickness.
    Matsnev EI; Sigaleva EE
    J Vestib Res; 2007; 17(5-6):313-21. PubMed ID: 18626141
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The effect of an ephedrine/caffeine combination as a supplement to a weight-reducing diet. A randomized, placebo-controlled, double-blind trial].
    Quaade F; Astrup A; Breum L; Toubro S; Hein P
    Ugeskr Laeger; 1992 Apr; 154(18):1258-63. PubMed ID: 1598695
    [No Abstract]   [Full Text] [Related]  

  • 43. Relative efficacy of the proposed Space Shuttle antimotion sickness medications.
    Hordinsky JR; Schwartz E; Beier J; Martin J; Aust G
    Acta Astronaut; 1982; 9(6-7):375-83. PubMed ID: 11541691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autonomic function and plasma catecholamines following stressful sensory stimuli.
    Kohl RL
    Aviat Space Environ Med; 1993 Oct; 64(10):921-7. PubMed ID: 8240196
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of drugs in altering susceptibility to motion sickness in aerobatics and the slow rotation room.
    Deane FR; Wood CD; Graybiel A
    Aerosp Med; 1967 Aug; 38(8):842-5. PubMed ID: 6049246
    [No Abstract]   [Full Text] [Related]  

  • 47. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study.
    Gil A; Nachum Z; Tal D; Shupak A
    Clin Neuropharmacol; 2012; 35(1):37-9. PubMed ID: 22139622
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy of low-dose intranasal scopolamine for motion sickness.
    Simmons RG; Phillips JB; Lojewski RA; Wang Z; Boyd JL; Putcha L
    Aviat Space Environ Med; 2010 Apr; 81(4):405-12. PubMed ID: 20377145
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectivity of antimotion sickness drugs during artificial gravity simulations.
    Green JA
    Aerosp Med; 1973 Nov; 44(11):1255-60. PubMed ID: 4586812
    [No Abstract]   [Full Text] [Related]  

  • 50. Onset of action of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg in subjects aged 12 years with moderate to severe seasonal allergic rhinitis: a pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies.
    Berkowitz RB; McCafferty F; Lutz C; Bazelmans D; Godfrey P; Meeves S; Liao Y; Georges G
    Clin Ther; 2006 Oct; 28(10):1658-69. PubMed ID: 17157121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study.
    Marcus DA; Furman JM
    Med Sci Monit; 2006 Jan; 12(1):PI1-7. PubMed ID: 16369474
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The vestibulo-ocular reflex (VOR) under the influence of cinnarizine.
    Doweck I; Gordon CR; Spitzer O; Melamed Y; Shupak A
    J Vestib Res; 1994; 4(3):215-20. PubMed ID: 7921339
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Accidental mydriasis from scopolamine patches.
    Rosen NB
    J Am Optom Assoc; 1986 Jul; 57(7):541-2. PubMed ID: 3745760
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transdermal scopolamine in motion sickness.
    Cronin CM; Sallan SE; Wolfe L
    Pharmacotherapy; 1982; 2(1):29-31. PubMed ID: 6927209
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reducing the dose of combined caffeine and ephedrine preserves the ergogenic effect.
    Bell DG; Jacobs I; McLellan TM; Zamecnik J
    Aviat Space Environ Med; 2000 Apr; 71(4):415-9. PubMed ID: 10766467
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phenytoin for motion sickness: clinical evaluation.
    Knox GW; Woodard D; Chelen W; Ferguson R; Johnson L
    Laryngoscope; 1994 Aug; 104(8 Pt 1):935-9. PubMed ID: 8052077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Use of No-Shpa in combination with vitamins in motion sickness].
    Usachev VV; Sabaev VV; Matveev AD; Popov AG
    Kosm Biol Aviakosm Med; 1981; 15(3):82-3. PubMed ID: 7289553
    [No Abstract]   [Full Text] [Related]  

  • 58. Preoperative transdermal scopolamine does not reduce the level of nausea and frequency of vomiting after laparoscopic cholecystectomy.
    Sohi HS; Heipel J; Inman KJ; Chinnick B; Cunningham DG; Holliday RL; Girotti MJ
    Can J Surg; 1994 Aug; 37(4):307-12. PubMed ID: 8055388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.
    Golding JF; Wesnes KA; Leaker BR
    Br J Clin Pharmacol; 2018 Jul; 84(7):1535-1543. PubMed ID: 29522648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Republic of Singapore Navy's Scopoderm TTS study: results after 2,200 man-days at sea.
    How J; Lee PS; Seet LC; Tan PK
    Aviat Space Environ Med; 1988 Jul; 59(7):646-50. PubMed ID: 3044323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.